Read our latest publication together with NAIAD and Johns Hopkins University on the T cell response to the mutations found in the omicron variant of SARS-CoV-2

March 21, 2022

ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University. Read our paper here: Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8+ T-Cell Epitopes Identified in COVID-19 Convalescent Individuals

ImmunoScape Inks Licensing Deal with Pure MHC to Advance Development of Novel TCR- Based Therapies

February 16, 2022

SINGAPORE, SAN DIEGO, OKLAHOMA CITY, and AUSTIN – February 16, 2022 – ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology, today announced that it has signed a licensing deal with Pure MHC, LLC, a target discovery and development company, to pursue TCR-T […]

ImmunoScape Appoints Renowned Immuno-Oncology Expert Adrian Woolfson, BM BCh, PhD, to Board of Directors

July 28, 2021

SINGAPORE and SAN DIEGO – July 28, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced that Adrian Woolfson, BM BCh, PhD, has joined its Board of Directors and Scientific Advisory Board to help guide the company’s strategy as it expands into […]

ImmunoScape Expands its Executive and Scientific Teams to Extend Use of its Deep Immunomics Platform into Drug Discovery

June 29, 2021

SINGAPORE and SAN DIEGO – June 29, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has made three strategic additions to its global team to expand the use of its innovative technology platform for drug discovery. The new hires include […]

ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery

April 14, 2021

SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an […]

T cells recognize recent SARS-CoV-2 variants (NIAID, Johns Hopkins University, & ImmunoScape Collaboration)

March 30, 2021

ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University to better understand if the CD8+ T-cell responses from COVID-19 recovered individuals still recognize the major SARS-CoV-2 variants. Out of 45 mutations assessed from the SA, UK and Brazil variants, only one mutation within the SA variant, B.1.351 Spike protein overlapped with […]

Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus vaccine

March 9, 2021

Valo Therapeutics Limited (Valo Tx), the developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases, today announced the completion of a successful collaboration with the biotechnology company ImmunoScape (Singapore and San Diego) to identify immunogenic peptides for the development of a pan Coronavirus vaccine.

Geoff Nosrati

ImmunoScape Announces Chief Business Officer to Lead U.S. Expansion

February 22, 2021

Biotech executive Geoff Nosrati, Ph.D. has been named Chief Business Officer as the company expands to San Diego to accommodate growing list of U.S. partnerships

ImmunoScape Establishes Scientific Advisory Board of Distinguished Immunology Experts

January 28, 2021

World-class scientists and physicians from Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital, Massachusetts General Hospital and Harvard Medical School, will provide unique research perspectives and strategic direction 

Johns Hopkins University/NIAID Collaboration

January 26, 2021

ImmunoScape is thrilled to announce its collaboration with Johns Hopkins University/NIAID to deeply profile the SARS-CoV-2-specific CD8 T cell response in COVID-19 recovered donors. Gaining insights into T cells that interact with specific regions of the SARS-CoV-2 virus, and  provide long-lasting immunity against COVID-19, may help spur development of the next generation of vaccines. Press […]